Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
Aims. To examine the potential differences between multiple daily injection (MDI) regimens based on new long-acting insulin analogues (glargine or detemir) plus prandial insulin aspart and continuous subcutaneous insulin aspart infusion (CSII) in patients with poorly controlled type 2 diabetes. Met...
Main Authors: | Lv, Wen-shan, Li, Li, Wen, Jun-ping, Pan, Rong-fang, Sun, Rui-xia, Wang, Jing, Xian, Yu-xin, Cao, Cai-xia, Gao, Yan-yan |
---|---|
Format: | Online |
Language: | English |
Published: |
Hindawi Publishing Corporation
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662171/ |
Similar Items
-
Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes
by: GAO, GUAN-QI, et al.
Published: (2014) -
The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
by: Cengiz, Eda, et al.
Published: (2012) -
Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial
by: Kumar, Ajay, et al.
Published: (2016) -
Detemir as a once-daily basal insulin in type 2 diabetes
by: Nelson, Scott E
Published: (2011) -
Changes in Glycemic Control and Quality of Life in Pediatric Type 1 Diabetics
with Continuous Subcutaneous Insulin Infusion of Insulin Aspart Following Multiple Daily
Injection Therapy
by: Kawamura, Tomoyuki, et al.
Published: (2008)